TAF与TDF在CHB患者中的疗效和安全性结果

antiHBVren

A Phase 3 Study Comparing Tenofovir Alafenamide (TAF) to Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAg-Negative, Chronic Hepatitis B (CHB): Efficacy and Safety Results at Week 96 Reported by Jules Levin EASL 2017 April 19-21 Amsterdam Netherlands Maurizia Brunetto1, Young-Suk Lim2, Edward Gane3, Wai Kay Seto4, Marina Osipenko5, Sang Hoon Ahn6, Harry L.A. Janssen7,8, Akash Shukla9, Wan-Long Chuang10, Huy Trinh11, Mustafa K. Celen12, John F. Flaherty13, Audrey H. Lau, 13 Anuj Gaggar13, Vithika Suri13, Neeru Bhardwaj13, Kyungpil Kim13, G. Mani Subramanian13, Calvin Pan14, Namiki Izumi15, Patrick Marcellin16, Henry L.Y. Chan17, Maria Buti18 1University Hospital of Pisa, Italy; 2Asan Medical Center, Seoul, South Korea ; 3Auckland Clinical Studies, Auckland, New Zealand; 4Queen Mary Hospital, Hong Kong, China; 5Novosibirsk State Medical University, Novosibirsk, Russia; 6Yonsei University, Seoul, Korea, ; 7Toronto Western Hospital, Toronto, Ontario, Canada; 8Erasmus Medical Center, Rotterdam, Netherlands; 9KEM hospital, Mumbai, India; 10Kaohsiung Medical University Hospital, Taiwan; 11Silicon Valley Research Institute, San Jose, United States; 12Dicle Üniversitesi Hastanesi Enfeksiyon Hastaliklari Anabilim Dali, Diyarbakir, Turkey; 13Gilead Sciences, Inc., Foster City, CA, USA; 14New Discovery, LLC, New York, NY, USA; 15Musashino Red Cross Hospital, Tokyo, Japan; 16Hôpital Beaujon, Clichy, France; 17The Chinese University of Hong Kong, China; 18Hospital General Universitari Vall d'Hebron, Barcelona, Spain